Podcasts

E-Books

Videos

Articles

Clinical

Bincy P. Abraham, MD, MS, AGAF, FACG, is a professor of Clinical Medicine at Houston Methodist Academic Institute. She is also the distinguished professor and director of the Fondren Inflammatory Bowel Disease Program at the Underwood Center for Digestive Disorders and director of Gastroenterology Fellowship Program at Houston Methodist Hospital.

Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them. 

Opinion: Embrace the Era of Next-Generation Biologics

Tony Hagen is senior managing editor for The Center for Biosimilars

The rheumatology and gastroenterology biosimilar candidate would enter the lucrative market established by Humira.

Alvotech Files for US and EU Approval of Adalimumab Biosimilar

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars. 

IGBA Launches Global Biosimilars Week

Investigators looked at adherence in patients who switched from reference infliximab during treatment for rheumatologic and gastrointestinal treatment. 

High Adherence Noted Among Infliximab Biosimilar Users

Poster presentations at the American College of Rheumatology (ACR) Convergence 2020 meeting shed light on performance of adalimumab versions. 

ACR Abstract Roundup: Pfizer and Celltrion Agents Demonstrate Safety, Efficacy

Separate studies including one on application methods for CT-P17 were reported at the American College of Rheumatology Convergence 2020 meeting.

Celltrion's CT-P17 Adalimumab Biosimilar Candidate Demonstrates Equivalence

This study of specialty drug spending looks beyond rebates to evaluate growth in spending from 2010 to 2017. 

Study: Specialty Drug Spending Net of Rebates Soars for Private Insurance, Medicare Part D

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

The FDA may require comparative clinical efficacy for biosimilar approval, but on top of all the other required and available evidence, these trials add little value, Sarfaraz K. Niazi, PhD, states. 

Ten Reasons Why Biosimilar Candidates Should Not Be Tested for Clinical Efficacy

Amgen said its sales results for Mvasi (bevacizumab) and Kanjinti (trastuzumab) give it confidence that the US market for biosimilars is more viable than generally perceived.

Mvasi, Kanjinti Add Heft to Amgen's Third-Quarter Sales

European investigators have derived a set of core principals for developing higher utilization of biosimilars. 

Gastroenterology